Emerging serine-threonine kinase inhibitors for treating ovarian cancer

  title={Emerging serine-threonine kinase inhibitors for treating ovarian cancer},
  author={Asaf Maoz and Marcia A. Ciccone and Shinya Matsuzaki and Robert L. Coleman and Koji Matsuo},
  journal={Expert Opinion on Emerging Drugs},
  pages={239 - 253}
ABSTRACT Introduction: Ovarian cancer is the leading cause of gynecologic cancer death, owing to high rates of incurable, recurrent disease after initial treatment. Serine threonine kinases (STKs) have been proposed as potential therapeutic targets in ovarian cancer because of their role in the initiation and progression of cancers. Experience in non-ovarian cancers suggests that STK inhibitors are active against tumors with specific molecular alterations. Areas covered: This review discusses… 
Ovarian Cancer: Molecular Classification and Targeted Therapy
This chapter provides an overview of the critical molecular pathways activated in the ovarian cancer subtypes with its druggable targets studied in ovarian cancer and highlights the implications of miRNAs in chemoresistance and sensitivity in the regulation of ovarian cancer.
Targeting Six Hallmarks of Cancer in Ovarian Cancer Therapy.
This review is intended to provide a comprehensive description of the molecular alterations involved in ovarian cancer carcinogenesis and of emerging biological agents and combined strategies that target aberrant pathways, which might shed light in future ovarian cancer treatment.
Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cord–Stromal Tumors: A Contemporary Review
The rarity and complexity of non-epithelial ovarian tumors warrant collaboration and efficient clinical trial design, including high-quality molecular characterization, to guide future efforts.
Expression and molecular profiles of the AlkB family in ovarian serous carcinoma
The results indicated that the expression of AL KBH1/3/5/8 and FTO was lower in OV patients while ALKBH2/4/6/7 expression was higher, and the functions of AlkB family were linked to several cancer-associated signaling pathways, including chemokine receptor signaling.


Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature
STK inhibitor-based therapy showed modest activity for recurrent epithelial ovarian cancer with reasonable clinical benefit rates, suggesting its potential utility for maintaining disease stability if supported by future studies.
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
This review highlights the antitumor activity of sorafenib across a variety of tumor types, including renal cell, hepatocellular, breast, and colorectal carcinomas in the preclinical setting.
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)
The pipeline of Akt inhibitors and their preclinical and clinical examination status are explored, presenting the potential clinical application of these agents as a monotherapy or in combination with ionizing radiation, other targeted therapies, or chemotherapy.
Alisertib: a review of pharmacokinetics, efficacy and toxicity in patients with hematologic malignancies and solid tumors
Alisertib is an oral aurora kinase inhibitor which has been shown to induce cell-cycle arrest and apoptosis in preclinical studies and may allow it to be combined with other oral agents or traditional chemotherapy across a wide variety of malignancy types.
Epithelial ovarian cancer: Evolution of management in the era of precision medicine
To improve survival in this aggressive disease, access to appropriate evidence‐based care is requisite and individualized precision medicine will require prioritizing clinical trials of innovative treatments and refining predictive biomarkers that will enable selection of patients who would benefit from chemotherapy, targeted agents, or immunotherapy.
Treatment of recurrent ovarian cancer.
Preliminary data from the prospective AGO-DESKTOP III give evidence that surgery for ROC seems to be of benefit for selected patients with platinum-sensitive relapse undergoing complete resection, and the integration of surgery, with a 'personalized' approach by the use of antiangiogenic agent and of PARP inhibitors is affecting survival of patients with recurrent disease and will help epithelial ovarian cancer to become a chronic disease.